A clinical trial from Wake Forest University School of Medicine shows that two widely available medications, the diabetes ...

Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction PRESS ...

Two widely available medicines can safely improve brain health in those with early Alzheimer’s disease, a new study has found ...

- The breakthrough approval expands the existing indication of Jardiance ® to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that ...

- FDA approval marks a significant breakthrough for the approximately 3 million adults in the U.S. with heart failure with preserved ejection fraction, which has been classified as "the single largest ...

- Empagliflozin is the first and only SGLT2 inhibitor approved for this patient population- More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. Jardiance is not ...

The double-blind EMPEROR-Reduced trial enrolled 3730 adults with HFrEF, with and without diabetes. Boehringer Ingelheim and Lilly announced positive topline results from a phase 3 trial evaluating the ...

In the phase III EMPEROR-Preserved trial, among nearly 6,000 patients with chronic HF with preserved ejection fraction (HFpEF), empagliflozin was able to slow kidney function decline over the 172-week ...

- The positive opinion is based on the landmark EMPEROR-Preserved Phase III trial, which showed significant outcomes in patients with heart failure with left ventricular ejection fraction over 40% 1 - ...

The federal government will add a medicine for chronic kidney disease into the Pharmaceutical Benefits Scheme. More than ...

Jardiance is a diabetes medication that manages blood glucose levels, it is also used as a weight loss treatment. The active drug, Empagliflozin, although not technically a weight loss medication, ...

- More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. RIDGEFIELD, Conn. and INDIANAPOLIS, June 21, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has ...